Knopp Biosciences to Present at 2019 BIO CEO & Investor Conference
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today announced that the management will present and conduct face-to-face meetings at the 2019 BIO CEO & Investor Conference, to be held in New York, NY on February 11-12.
Michael Bozik, M.D., President and CEO of Knopp Biosciences, is scheduled to present on Tuesday, February 12 at 11:15 a.m. Eastern Time.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 development in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, tinnitus, and neuropathic pain. Please visit www.knoppbio.com .
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-MOBILEIRON22.8.2019 09:02:07 CEST | Press release
MobileIron Named a Leader Again in the Second Gartner Magic Quadrant for Unified Endpoint Management Tools
MIRACOR-MEDICAL22.8.2019 08:02:07 CEST | Press release
Miracor Medical Granted FDA Breakthrough Device Designation for the PiCSO Impulse System
MORI-BUILDING22.8.2019 06:02:06 CEST | Press release
Mori Building Unveils Massive Urban Regeneration Project in Central Tokyo
MUNDIPHARMA22.8.2019 01:03:13 CEST | Press release
Mundipharma Announces the Licence Extension Submission for Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin) to the European Medicines Agency
NY-TRITON-DIGITAL21.8.2019 22:02:07 CEST | Press release
Triton Digital Releases Webcast Metrics Rankings for the Top Digital Audio Properties for April 2019
CELSIUS-NETWORK21.8.2019 17:17:05 CEST | Press release
Celsius Partners With Tether to Bring USDT its Highest Interest-earning Wallet at 10.53% APR
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom